#1CYTEK TRANSCEND THE CONVENTIONAL Credit Suisse Conference Terranea Resort Dr. Wenbin Jiang, CEO November 2022#2Safe Harbor Statement This presentation and the accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding the size and growth of the cell analysis market; Cytek's anticipated total addressable market; Cytek's business and operational strategy; Cytek's prospective products; Cytek's business development plans and opportunities; Cytek's anticipated customer mix and collaborations plans; and objectives of management for future operations are forward looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, and financial needs. All statements other than statements of historical facts contained in this presentation, including, without limitation, statements The words "may," "will," "expect," "anticipate," "aim,” “estimate,” “intend," "plan," "believe," "is/are likely to," "potential," "continue" and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to risks relating to global economic and market conditions; the continued impacts of COVID-19; supply chain risks and Cytek's dependence on certain sole and single source suppliers; competition; market acceptance of Cytek's current and potential products; Cytek's ability to manage the growth and complexity of its organization; Cytek's ability to maintain, protect and enhance its intellectual property; and Cytek's ability to continue to stay in compliance with its material contractual obligations, applicable laws and regulations. Information on these and additional risks and uncertainties and other information affecting Cytek's business and operating results is contained in Cytek's Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, and in its other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Except as required by applicable law, Cytek does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Certain information contained in this presentation and statements made orally during this presentation relate to or are based on studies, publications, surveys and other data obtained from third-party sources and Cytek's own internal estimates and research. While Cytek believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. While Cytek believes its internal research is reliable, such research has not been verified by any independent source. Cytek's estimates are derived from publicly available information, management's knowledge of the Cytek's industry and management's assumptions based on such information and knowledge, which they believe to be reasonable. This data involves a number of assumptions and limitations which are necessarily subject to a high degree of uncertainty and risk due to a variety of factors. This presentation contains adjusted EBITDA and adjusted gross margin, financial measures that are not in accordance with Generally Accepted Accounting Principles (GAAP). Reconciliations of adjusted EBITDA and adjusted gross margin to the most comparable GAAP measures are included at the end of this slide presentation. We present adjusted EBITDA and adjusted gross margin because we believe they are frequently used by analysts, investors and other interested parties to evaluate companies in our industry and it facilitates comparisons on a consistent basis across reporting periods. Further, we believe it is helpful in highlighting trends in our operating results because it excludes items that are not indicative of our core operating performance. Cytek, Full Spectrum Profiling, FSP, Northern Lights, and cFluor are trademarks or registered trademarks of Cytek Biosciences, Inc. Other trademarks appearing in this presentation are the property of their respective holders. CYTEK TRANSCEND THE CONVENTIONAL 2#3Cytek's Leadership Team Wenbin Jiang, Ph.D. Chief Executive Officer Cosemi LUMENTUM UGHTSPEED BANOWIOTH> Valerie Barnett General Counsel Dermira FFLUIDIGM Maria Jaimes, M.D. VP, Applications BD CYTEK TRANSCEND THE CONVENTIONAL WILSON SONSINI Ming Yan, Ph.D. Chief Technology Officer BD Ne Photonics Binding Site Chris Williams Chief Operating Officer Thermo Fisher SCIENTIFIC Connie Wedel Chief People Officer ARGEN™ Mark Edinger VP, Scientific Affairs Patrik Jeanmonod Chief Financial Officer COVANCE BDQSolutions CORE BRANDS Allen Poirson, Ph.D. SVP, Marketing and Corporate Development Acculmage two AR SONY BIOTECHNOLOGY Melik Ulusu VP, Operations & Integrated Supply Chain BD PerkinElmer Todd Garland Chief Commercial Officer BD CareFusion CardinalHealth Paul Goodson Head of Investor Relations Invitrogen living science sequenom. XOMA Dave Kennedy VP, Global Sales & Service SARTORIUS amnis BD 3#4Investing to Capture the Cell Analysis Opportunity Validated Technology Platform Broad Customer Base and Global Presence Strong Financial Profile 1,501 Units Placed 881 Publications CYTEK TRANSCEND THE CONVENTIONAL 900+ Customers 40+ Countries $155M $21M TTM Revenue/ A-EBITDA $342M Cash No debt CE-IVDD Tonbo Cell Sorter Reagents Northern Lights Aurora B 2022 2021 2021 2020 2018 2017 4#5Global Scale and Reach with Diversified Revenue Mix Since launch of Aurora Series in 2017... 900+ Customers 550+ Employees 150+ Biopharma Companies 40+ Countries WW Applications, Service & Sales % Revenue by Industry 42% O 58% 1 CYTEK TRANSCEND THE CONVENTIONAL Seattle 1. YTD Q3 2022 Fremont (Headquarters). Academic and Government-Owned Institutions ■ Pharmaceutical and Biotechnology Companies, Distributors and CROS San Diego Bethesda Amsterdam % Revenue by Region¹ USA 59% EMEA 24% Wuxi Shanghai APAC 17% Tokyo#6Our FSP Platform Allows Us to Address the Broader Cell Analysis Market $1.0B Single Cell Analysis $1.6B Cell Counting & QC CYTEK TRANSCEND THE CONVENTIONAL $8B Initial TAM (Cell Analysis Market in 2019 Addressable by Flow Cytometry) $1.9B Cell Proliferation $3.0 B Cell ID $1.1B Cell Structure $1.3B Target ID $1.3B Cell Interaction $8B Additional TAM (Cell Analysis Market in 2019 Not Currently Addressable by Flow Cytometry) $2.4B Cell Viability $2.4B Cell Signaling $23B Long-Term TAM (Total Cell Analysis Market in 2024) Marine Biology Water Supply Contamination 8) Alternative Biofuels#7Cytek Technology Enables Applications. Total Peer Reviewed Scientific Publication by Application 9% 5% 4% 12% 2% 12% 2% 2% 21% 13% 13% ■Infectious disease. ■ Immunology Immunotherapy ■COVID-19 ■ Oncology Immuno-oncology ■ Inflammation ■ Neurobiology Drug discovery ■Auto-immune disorder ■ Genomics Transplantation ■ Viral infection Cell # Publications 3 Q3 '18 Cancer Research 6 Q4 '18 9 AAGR 11 Q1 '19 Q2 '19 JCI INSIGHT 18 Q3 '19 me pc HC- que pofsit 25 Q4 '19 45 Q1 20 70 The Journal Immunology 111 172 242 Q2 '20 Q3 '20 Q4 '20 Q1 '21 nature INSIDE GREEN FLUORESCENT PROTEIN 325 414 Q2 '21 Q3 '21 516 Q4 '21 Science Advances AAAAS 652 Q1 22 768 881 Q2 '22 Q3'22 7#8Why Customers Choose Cytek .LO $ 隱 Deeper assessment of patient immune status -- before and after treatment -- for many applications including cancer, COVID, inflammation, drug discovery Fully Standardized across experiments and laboratory sites More powerful system at a lower cost with minimal learning curve Isolate rare cells that cannot be seen on other systems for deeper insights Maximize the value of a lab sample with more information in less time with fewer errors Over 800 scientific peer-reviewed publications in less than 5 years CYTEK TRANSCEND THE CONVENTIONAL ∞#9We Provide an End-to-End Platform of FSP Solutions Aurora Cell Sorter Specificity CD3 CD14 CD45 Violet Instruments Fluorochrome cFluor V420 cFluor V450 cFluor V547 CYTEK TRANSCEND THE CONVENTIONAL 0 Specificity CD8 CCR7 IgD CD45RA CD19 CD25 Blue Northern Lights Han Fluorochrome cFluor B515 cFluor BYG575 cFluor BYG667 cFluor 8690 cFluor BYG710 cFluor BYG781 Automatic sample loader FOOTER Specificity CD127 CD16 CD56 CD4 Viability CD27 Red Fluorochrome cFluor R659 cFluor R668 cFluor R720 Services & Application support cFluor R780 ViaDye Red cFluor R840 Reagents and Kits 2000 CYTER FULL SPECTRUM 5-LASER CYTOMETRY AT A GLANCE CYTEK CYTEK SELAS Dimensionality Reduction CYTEK Data Acquisition and Analysis Software 9#10Cytek's Four Business Pillars Instruments Performance Intelligence Ease of use ● ● Compact Lowest cost CYTEK TRANSCEND THE CONVENTIONAL UNAVA FOOTNOTE Applications Enabler Panels/kits Flexibility Functionality/Purposes Volume/repeating UNNA Bioinformatics Storage Analysis Optimization Management Exchanges ● ● ● ● ● UNNA are are are Clinical ● ● ● ● ● Regulatory LDT Menu Al Standardization UNNA 10#11C Our FSP Technology is Powered by Patented Innovative Designs 4 CE BCTUR I APD DETECTOR MODULE DETAIL DE EXTCR2 DE EXCR DE ESTRA CYTEK AURORA CYTEK TRANSCEND THE CONVENTIONAL Maximize Resolution & Accuracy SUVEN VIRTONS LAGERS A WAPO DETECTOR MODULE FOOTNOTE VIOLET APD DETECTOR MODULE FLOW CELL BLUE APO DETECTOR MODULE SAMPLE поспортоз RED AND DETECTOR MODULE YORK APP DETECTOR MODULE Optimized Signal-to-Noise Ratio B LTRAVIOLET CHANK-SI VIOLET CHANNELS BLUC C&CHANNELS SPECTROFLO DISPLAY YELLOW-GREEN RED CHANNELS OR CHANNELS High Resolution D 100 quantum efficiency (%) 10 0.1 200 PMT APD photodiode 400 600 800 wavelength (nm) Valuable Insights 1000 1200 A The fluorescence spectrum from each laser source is collected from multiple laser excitation B The fluorescence from each laser source is collected by each corresponding detector array module C Use of APD detectors maximizes sensitivity and enables broad wavelength responses D The combination of our patented optical design with APD detectors yields high- resolution data at an optimized signal-to-noise ratio 11#12Advancing Cell Analysis with Our Unique FSP Technology Cytek's FSP Technology Conventional 80 80 70 80 50 30 20 10 n 300 Ignored PE Channel Compensated CYTEK TRANSCEND THE CONVENTIONAL 7:00 FITC = Green!... or emission from 515-545 (530/30 BP) zul FOOTNOTE PE cFluor YG584 UV Channe Be Channe Unmixing algorithm ENTIRE emission spectrum is captured across the different module & stitched together to create a spectral signature that combines emission information of fluorochrome excited by all onboard lasers X/G Channels And Cha CD8 APC 13 å 꿈 APC Alexa Fluor 647 0 4.0M- 2.0M 1.0M- 0- NK cells Aurora Full Spectrum NK cells M 0 10 10³ CD56 Alexa 647 Non T cells THE Tong 10¹ APC 10⁰ Unmixing T cells 10ª CD3 FITC CD8 APC 10⁹ -10³ Alexa Fluor 647 -10* 10⁰ NK T cells NK T cells 0 101 CD56 Alexa 647 Our FSP platform was purpose- built to advance the next generation of cell analysis by delivering deep insights, high throughputs and ease of use FSP technology enables high sensitivity and high throughput without compromising data quality Allows use of many dyes simultaneously with optimal resolution, which is not possible with conventional cytometers FSP is able to extract autofluorescence to enhance resolution 12#13Strong and Growing Base of Instrument Placements 303 4Q19 376 1Q20 CYTEK TRANSCEND THE CONVENTIONAL 447 2Q20 548 3Q20 657 4Q20 751 1Q21 CAGR (Q4'19 - Q3'22) 79% 855 2Q21 970 3Q21 1110 4Q21 1226 1Q22 1359 2Q22 1501 3Q22 13#14Quarterly Revenue and Adjusted Gross Margin % Q1-20 to Q3-22 ($MM) $18.0 $1.9 47% $16.1 Q1'20A CYTEK TRANSCEND THE CONVENTIONAL $19.1 $1.7 43% $17.5 Q2'20A $25.1 $1.9 62% $23.2 Q3'20A $30.6 $2.0 64% $28.6 Q4'20A Service Revenue Reconciliation of Non-GAAP figures are in the appendix $24.3 $1.6 60% $22.7 Q1'21A $30.4 $1.7 65% $28.7 Q2'21A $34.4 $2.2 64% $32.2 Q3'21A Product Revenue $38.9 $2.9 63% $36.0 Q4'21A $35.1 $3.6 60% $31.5 Q1'22A -Adj-GP $40.2 $40.5 $3.1 63% $37.1 Q2'22A $4.1 68% $36.4 Q3'22A Q3-2022 Under Review • Total Revenue $40.5 Cytek added another 142 instruments now total base at 1,501 • Service revenue growing steadily to $4.1m up from $2.2m in 2021 on more instruments coming off warranty • Adjusted GP margin 68% compared to 64% in the third quarter of 2021 14#15Revenue & Adj. EBITDA ($MM) Adj. EBITDA Tot. Revenue A-EBITDA % CYTEK TRANSCEND THE CONVENTIONAL $18.0 -2% Q1¹20 $(0.4) Q1'20 $(0.4) $18.0 -2% FOOTER $19.1 2% $0.4 Q2'20 Q2'20 $0.4 $19.1 2% 28% $7.1 $25.1 Q3'20 Q3'20 $7.1 $25.1 28% 27% $8.3 $30.6 Q4'20 Q4'20 $8.3 $30.6 27% Tot Revenue $24.3 7% $1.8 Q1'21 Q1'21 $1.8 $24.3 7% 15% $4.7 $30.4 Q2'21 Q2'21 $4.7 $30.4 15% A-EBITDA % $34.4 16% $5.5 Q3'21 Q3'21 $5.5 $34.4 16% Column1 $39.9 14% $5.5 Q4'21 Q4'21 $5.5 $39.9 14% $35.1 9% $2.2 Q1'22 Q1'22 $2.2 $35.1 9% $40.2 12% $4.8 Q2'22 Q2'22 $4.8 $40.2 12% $40.5 17% $7.3 Q3'22 Q3'22 $7.30 $40.48 17% 15#16Cytek's Operational and Shareholder Goals Capital Efficiency Operation Excellence CYTEK TRANSCEND THE CONVENTIONAL Maximize Free Cash Flow FOOTNOTE Commitment to Shareholder Value Creation Maintain Positive EBITDA on annual basis Execution Speed Smart Acquisitions, Licenses and Joint Ventures 16#17CYTEK TRANSCEND THE CONVENTIONAL Credit Suisse Conference Terranea Resort Dr. Wenbin Jiang, CEO November 2022#18CYTEK TRANSCEND THE CONVENTIONAL Appendix R#19Note: Fiscal Quarter Non-GAAP Adjusted GP Reconciliation ($ in thousands) Non-GAAP Adjusted Gross Profit Reconciliation ($ in thousands) GAAP Gross Profit Adjustments Amortization of Acquisition-Related Intangible Ass Stock-Based Compensation Expense Non-GAAP gross profit Revenue Non-GAAP gross profit % FY20A 51,710 FY21A 79,144 0 237 232 1,508 51,942 I 80,888 92,839 127,950 56% 63% 1Q2020 2Q2020 8,375 8,270 0 29 8,404 17,988 47% 0 40 8,310 19,137 43% 3Q2020 4Q2020 1Q2021 2Q2021 3Q2021 4Q2021 1Q2022 15,615 19,450 14,487 19,745 21,276 23,636 20,177 0 38 15,653 25,095 62% 0 125 19,574 30,619 64% 0 0 0 112 120 559 14,599 19,864 21,835 24,272 30,408 34,376 65% 64% 60% 237 717 24,589 38,893 63% 2Q2022 3Q2022 24,558 26,861 57 64 708 749 20,941 25,372 35,064 60% 64 759 27,685 40,159 40,477 63% 68% CYTEK TRANSCEND THE CONVENTIONAL 19#20Note: Fiscal Quarter Non-GAAP Adjusted EBITDA ($ in thousands) Non-GAAP Adjusted EBITDA Reconciliation ($ in thousands) Net Income Adjustments Depreciation and Amortiza Provision for (Benefits from Interest Income Interest Expense Foreign currency exchange Litigation Settlement Loss on Lease Exit Cost Acqisition Related Expenses Stock-Based Compensatior Adjusted EBITDA Revenue Adjusted EBITDA % of Reven FY20A 19,411 578 (4,982) (110) 333 (463) 611 15,379 92,839 17% FY21A 1Q2020 2Q2020 3Q2020 4Q2020 3,027 (839) 8,111 5,600 6,539 1,241 2,921 (49) 1,741 1,481 105 198 (86) 0 104 161 (7,914) (15) 1 (79) 6,586 105 109 17,525 (411) 373 127,950 17,988 19,137 14% -2% 2% 179 387 (3) 2 (137) 125 7,091 25,095 28% 133 2,348 (5) 330 (350) 271 8,327 30,619 27% 1Q2021 2Q2021 101 2,671 169 50 (10) 375 663 456 1,804 24,272 7% 194 597 (9) 433 135 667 4,688 30,408 15% 3Q2021 1,420 194 655 (12) 442 388 4Q2021 (1,165) 685 1,619 (19) 492 295 1Q2022 2Q2022 3Q2022 (2,158) (701) 1,626 1,470 (1,144) (18) 590 422 347 229 2,455 3,837 3,008 5,542 5,491 34,376 38,893 35,064 2,998 16% 14% 9% 1,636 (700) (391) 647 331 3,934 4,756 40,159 12% 1,452 225 (1,584) 649 570 4,359 7,296 40,477 17% CYTEK TRANSCEND THE CONVENTIONAL 20